$IBIO niimbl.force.com/s/ NEW YORK , April 27, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE AMERICAN:IBIO) (“iBio” or the “Company”), a biologics contract manufacturing organization and biotechnology company, today provided an update on its COVID-19 vaccine manufacturing capacity and announced that it has joined the National Institute for Innovation in Manufacturing Biopharmaceuticals (“NIIMBL”), one of 14 institutes in the Manufacturing USA Network.
  • 5